Program
zanubrutinib
Also written as “Zanubrutinib”, “BGB-3111” and “BGB-3111 and Drug Cocktail”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, B-Cell, Marginal Zone, led by BeOne Medicines.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 358 open or running | phase 4since Sep 5, 2025 | Jan 9, 2015 | Dec 31, 2026phase 3 · NCT04170283 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Jan 9, 2015.
- Nov 18, 2019Phase 3 study in B-cell MalignanciesNCT04170283 · 955 enrolled · United States, Australia, China and more
- May 7, 2020Phase 2 study in COVID-19NCT04382586 · 63 enrolled · United States
- Jun 16, 2020Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT04436107 · 66 enrolled · China
- Jul 10, 2020Phase 1 study in HealthyNCT04470908 · 13 enrolled · United States
- Sep 9, 2020Phase 1 study in B-cell MalignanciesNCT04551963 · 26 enrolled · Australia
- Nov 18, 2020Phase 2 study in Lupus NephritisNCT04643470 · 177 enrolled · China
- Sep 27, 2021Phase 3 study in Lymphoma, FollicularNCT05100862 · 799 enrolled · United States, Argentina, Australia and more
- Sep 27, 2021Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05068440 · 65 enrolled · China
- Sep 16, 2022Phase 1 study in Healthy VolunteersNCT05547399 · 43 enrolled · United States
- Jan 23, 2023Phase 3 study in Primary Membranous NephropathyNCT05707377 · 178 enrolled · United States, Brazil, Canada and more
- Mar 2, 2023Phase 1 study in Healthy VolunteersNCT05767398 · 58 enrolled · United States
- Oct 3, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06073821 · 652 enrolled · United States, Australia, Austria and more
- Sep 5, 2025Phase 4 study in Waldenstrom MacroglobulinemiaNCT07169331 · 16 enrolled · China
- Dec 2, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07277231 · 500 planned · United States, Australia, Brazil and more
Ahead
- Dec 31, 2026Primary completion: phase 3 study in B-cell MalignanciesNCT04170283
- Oct 2027Primary completion: phase 3 study in Primary Membranous NephropathyNCT05707377
- Jul 2028Primary completion: phase 3 study in Lymphoma, FollicularNCT05100862
- Oct 31, 2028Primary completion: phase 4 study in Waldenstrom MacroglobulinemiaNCT07169331
TargetBeta
“An inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07277231Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more | 3 | Recruiting | Feb 2031 | 500 |
| NCT07169331Waldenstrom Macroglobulinemia · China | 4 | Active, not recruiting | Oct 31, 2028 | 16 |
| NCT06073821Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Feb 2032 | 652 |
| NCT05767398Healthy Volunteers · United States | 1 | Completed | Apr 28, 2023 | 58 |
| NCT05707377Primary Membranous Nephropathy · United States, Brazil, Canada and more | 3 | Active, not recruiting | Oct 2027 | 178 |
| NCT05547399Healthy Volunteers · United States | 1 | Completed | Dec 7, 2022 | 43 |
| NCT05100862Lymphoma, Follicular · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 2028 | 799 |
| NCT05068440Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | Mar 31, 2025 | 65 |
| NCT04643470Lupus Nephritis · China | 2 | Completed | Feb 26, 2024 | 177 |
| NCT04551963B-cell Malignancies · Australia | 1 | Completed | Feb 21, 2022 | 26 |
| NCT04470908Healthy · United States | 1 | Completed | Nov 10, 2020 | 13 |
| NCT04436107Lymphoma, Large B-Cell, Diffuse · China | 1 | Completed | Mar 28, 2024 | 66 |
| NCT04382586COVID-19 · United States | 2 | Completed | Feb 1, 2021 | 63 |
| NCT04170283B-cell Malignancies · United States, Australia, China and more | 3 | Active, not recruiting | Dec 31, 2026 | 955 |
| NCT04172246Leukemia, Lymphocytic, Chronic, B-Cell · Japan | 2 | Completed | May 10, 2023 | 55 |
| NCT04163783Healthy Volunteers · United States | 1 | Completed | Apr 18, 2017 | 6 |
| NCT04163523Healthy Volunteers · Australia | 1 | Completed | Jul 21, 2016 | 18 |
| NCT04116437Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | Jan 9, 2026 | 96 |
| NCT04002297Lymphoma, Mantle-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Apr 27, 2026 | 510 |
| NCT03734016Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Completed | Aug 8, 2022 | 652 |
| NCT03846427Lymphoma, B-Cell, Marginal Zone · United States, Australia, China and more | 2 | Completed | May 4, 2022 | 68 |
| NCT03561298Healthy Subjects · United States | 1 | Completed | Jun 7, 2018 | 18 |
| NCT03520920Lymphoma, B-Cell, Marginal Zone · China | 2 | Completed | Aug 28, 2020 | 41 |
| NCT03465059Hepatic Insufficiency · United States | 1 | Completed | Oct 19, 2018 | 29 |
| NCT03432884Healthy Volunteers · United States | 1 | Completed | Apr 16, 2018 | 40 |
| NCT03332173Waldenstrom Macroglobulinemia · China | 2 | Completed | May 8, 2019 | 44 |
| NCT03336333Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | May 7, 2021 | 590 |
| NCT03301181Healthy Volunteers: Asian, Non-Asian · United States | 1 | Completed | Nov 7, 2017 | 40 |
| NCT03206970Lymphoma, Mantle-Cell · China | 2 | Completed | Feb 15, 2019 | 86 |
| NCT03206918Recurrence · China | 2 | Completed | Jun 15, 2018 | 91 |
| NCT03189524Lymphoma, B-Cell · China | 1 | Completed | Aug 26, 2020 | 44 |
| NCT03145064Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | May 24, 2019 | 41 |
| NCT02795182Lymphoma · Australia, China | 1 | Completed | Dec 18, 2020 | 75 |
| NCT02569476Lymphoma · United States, Australia, Korea, Republic of | 1 | Completed | Sep 2, 2020 | 119 |
| NCT02343120B-cell Malignancies · United States, Australia, Italy and more | 2 | Completed | Mar 31, 2021 | 385 |
How it is read
Names in the registry
- “Zanubrutinib”, 30 entries
- “BGB-3111”, 2 entries
- “zanubrutinib”, 1 entry
- “BGB-3111 and Drug Cocktail”, 1 entry
- “BGB-3111 (Arm A)”, 1 entry
Codes read as this program: BGB3111.
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 7 studies
- Lymphoma, Large B-Cell, Diffuse, 3 studies
- Lymphoma, Mantle-Cell, 2 studies
- Waldenstrom Macroglobulinemia, 2 studies
- Lymphoma, B-Cell, Marginal Zone, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.